Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

被引：6

作者：

Arora, N. ^{[2
]}

Tewari, D. ^{[1
]}

Cowan, C. ^{[2
]}

Saffari, B. ^{[2
]}

Monk, B. J. ^{[2
]}

Burger, R. A. ^{[2
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Obstet Gynecol, Div Gynecol Oncol, Portland, OR 97239 USA

[2] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2008年 / 18卷 / 02期

关键词：

angiogenesis; bevacizumab; fallopian tube cancer;

D O I：

10.1111/j.1525-1438.2007.01026.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The targeting of angiogenesis pathways in the treatment of gynecological cancers is an exciting development in cancer therapy. Bevacizumab has been shown to have activity in ovarian cancer through its inhibition of the vascular endothelial growth factor. Fallopian tube carcinoma is a rare malignancy and is often treated in a similar manner as ovarian carcinoma. We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors.

引用

页码：369 / U2

页数：4

共 9 条

[1]

BURGER RA, 2005, ASCO ANN M P

[2]

DiSaia PJ, 2002, CLIN GYNECOLOGIC ONC, P377

[3]

GARCIA AA, 2005, ASCO ANN M P

[4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[5] Integrating behavior into health research and health care: One psychologist's journey [J].

Johnson, SB .

JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2004, 11 (02) :91-99

[6] Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer [J].

Monk, BJ ;

Choi, DC ;

Pugmire, G ;

Burger, RA .

GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :902-905

[7] Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer [J].

Monk, Bradley J. ;

Han, Ernest ;

Josephs-Cowan, Carol A. ;

Pugmire, Gordon ;

Burger, Robert A. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :140-144

[8] Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer [J].

Wedam, SB ;

Low, JA ;

Yang, SX ;

Chow, CK ;

Choyke, P ;

Danforth, D ;

Hewitt, SM ;

Berman, A ;

Steinberg, SM ;

Liewehr, DJ ;

Plehn, J ;

Doshi, A ;

Thomasson, D ;

McCarthy, N ;

Koeppen, H ;

Sherman, M ;

Zujewski, J ;

Camphausen, K ;

Chen, H ;

Swain, SM .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :769-777

[9] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].

Yang, JC ;

Haworth, L ;

Sherry, RM ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Steinberg, SM ;

Chen, HX ;

Rosenberg, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434

← 1 →